Aptinyx Inc. (NASDAQ:APTX – Get Rating) saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 2,890,000 shares, a decrease of 11.6% from the March 31st total of 3,270,000 shares. Approximately 6.8% of the company's shares are short sold. Based on an average daily volume of 3,400,000 shares, the days-to-cover ratio is presently 0.9 days.
Aptinyx Price Performance
Shares of APTX opened at $0.12 on Friday. The business's 50-day moving average is $0.19 and its two-hundred day moving average is $0.30. The company has a quick ratio of 10.18, a current ratio of 10.18 and a debt-to-equity ratio of 0.58. Aptinyx has a fifty-two week low of $0.11 and a fifty-two week high of $0.96.
Get Aptinyx alerts:Wall Street Analysts Forecast Growth
A number of research firms have weighed in on APTX. SVB Securities lowered Aptinyx from an "outperform" rating to a "market perform" rating in a report on Wednesday, March 1st. HC Wainwright lowered Aptinyx from a "buy" rating to a "neutral" rating in a report on Tuesday, March 7th. Finally, SVB Leerink restated a "market perform" rating and set a $0.50 target price on shares of Aptinyx in a report on Wednesday, March 1st. Seven analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Aptinyx currently has an average rating of "Hold" and an average price target of $1.38.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC lifted its stake in Aptinyx by 10.8% in the 4th quarter. Millennium Management LLC now owns 1,333,622 shares of the company's stock valued at $391,000 after buying an additional 129,635 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Aptinyx by 14.3% in the 4th quarter. Renaissance Technologies LLC now owns 618,226 shares of the company's stock worth $176,000 after purchasing an additional 77,200 shares in the last quarter. HBK Sorce Advisory LLC lifted its stake in Aptinyx by 100.0% in the 4th quarter. HBK Sorce Advisory LLC now owns 52,000 shares of the company's stock worth $53,000 after purchasing an additional 26,000 shares in the last quarter. Jane Street Group LLC lifted its stake in Aptinyx by 213.3% in the 3rd quarter. Jane Street Group LLC now owns 105,771 shares of the company's stock worth $39,000 after purchasing an additional 72,006 shares in the last quarter. Finally, RA Capital Management L.P. purchased a new position in Aptinyx in the 3rd quarter worth approximately $720,000. 45.93% of the stock is owned by hedge funds and other institutional investors.
Aptinyx Company Profile
(Get Rating)
Aptinyx Inc is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G.
Read More
- Get a free copy of the StockNews.com research report on Aptinyx (APTX)
- MarketBeat Week in Review – 4/24 – 4/28
- How to Invest in the Top Grocery Stocks for This Year
- Array Technologies Brings Solar Flare To 2023 Earnings Forecast
- Best Bank Stocks to Invest in Ahead of Rising Interest Rates
- How to Invest in Farmland: 7 Simple Ways
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.